Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplantation: New Risk Factors and New Therapeutic Options in a Changing World
Transplant Infectious Disease · 2026-05 · 28 (3)
DOI: 10.1111/tid.70197 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, online erschienen am 02.03.2026. Verfasst von Abby P Douglas und 1 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Infections in Cancer, Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Antifungal Agents, Invasive Fungal Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Invasive fungal diseases (IFD) have been recognized by WHO as of critical significance to human health requiring investment in surveillance, diagnostics, new treatments, and antifungal stewardship which should adopt a one health approach. IFD continue to complicate immunosuppressive therapies such as those for hematological malignancy and allogeneic hematopoietic cell transplantation (alloHCT) with a mortality of 30%–80%. However, new approaches to GVHD prophylaxis and treatment, longer survivorship, expanded access to transplantation, and haploidentical donors are changing the landscape of IFD post alloHCT. As well as expanding risk groups, the geographic reach of certain endemic infections is expanding due to climate change. Alongside these changes requiring clinicians to have heightened awareness of IFD even outside of traditional risk groups and geographic locations, new diagnostics and antifungal therapies are reaching the clinic. This is a timely development as rates of antifungal resistance to first line agents, such as azoles, are increasing and as more high‐risk patients receive antifungal prophylaxis, more resistant mold infections are increasingly seen. This review will address the changes in the field of IFD in patients receiving alloHCT and the evolving knowledge on new antifungal treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Centre for Infections in Cancer, Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Infectious Diseases and Immunology, Austin Health, Melbourne, Victoria, Australia.
- Department of Infectious Disease, University of Melbourne, Melbourne, Victoria, Australia.
- Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Abby P Douglas
Zitieren
APA
Douglas, A. P., & Slavin, M. A. (2026). Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplantation: New Risk Factors and New Therapeutic Options in a Changing World. Transplant Infectious Disease, 28(3). https://doi.org/10.1111/tid.70197
Vancouver
Douglas AP, Slavin MA. Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplantation: New Risk Factors and New Therapeutic Options in a Changing World. Transplant Infectious Disease. 2026;28(3). doi:10.1111/tid.70197
BibTeX
@article{Douglas2026,
author = {Douglas, Abby P and Slavin, Monica A},
title = {Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplantation: New Risk Factors and New Therapeutic Options in a Changing World},
journal = {Transplant Infectious Disease},
year = {2026},
volume = {28},
number = {3},
doi = {10.1111/tid.70197}
}
EUVIMED